read chart identify price action support and resistence volume entry and target lock in use indicator in high time frame
The GLP-1 drug market has rapidly expanded in recent years, driven by the success of treatments like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), both of which have revolutionized obesity and diabetes management. These drugs work by mimicking the effects of GLP-1, a hormone that regulates blood sugar and promotes satiety, leading to weight loss. The global market for GLP-1 drugs is forecast to reach over $50 billion by 2030. Altimmune’s pemvidutide (ALT-801), a dual GLP-1 and glucagon receptor agonist , is in a competitive space with these drugs. While pemvidutide has demonstrated strong weight loss results, its dual mechanism targeting both GLP-1 and glucagon receptors might offer additional metabolic benefits, such as enhanced fat burning. This could allow Altimmune to carve out a niche in the GLP-1 market , particularly if it offers advantages over existing treatments like semaglutide in terms of efficacy or side effect profile. Market share for Altimmune's pemvidutide depends on multiple factors, including trial results, regulatory approval, and commercial partnerships. If pemvidutide successfully reaches the market and captures even a conservative 5-10% of the total GLP-1 market, it could generate annual sales of $2.5 billion to $5 billion . Given the current market cap of Altimmune (around $400 million to $500 million), a successful launch could result in a significant market cap increase. If the drug achieves peak sales of $5 billion, Altimmune’s market cap could potentially surge to $5 billion to $10 billion , depending on investor sentiment, partnership deals, and commercialization strategy. Thus, a successful GLP-1 product like pemvidutide could drive substantial market cap growth for Altimmune, potentially by several billion dollars, in line with other biotech companies that have launched successful metabolic disorder treatments. Altimmune's GLP-1 drug, pemvidutide (also known as ALT-801), is a dual GLP-1 and glucagon receptor agonist currently in Phase II trials for obesity and metabolic disorders, including metabolic dysfunction-associated steatohepatitis (MASH). Early trial results have shown promising weight loss outcomes, with participants achieving up to 15.6% weight reduction in 48 weeks, significantly outperforming the placebo group. In addition to weight loss, the drug has also shown improvements in lipid profiles, such as reductions in triglycerides, total cholesterol, and low-density lipoprotein cholesterol. The drug's potential market is expected to be substantial, with forecasts predicting peak annual sales of up to $5 billion by 2030 Currently with a $400m market cap, and a drug that at this point seems to trump its competitors, ALT's future prospects look very promising. With a potential to see upwards of 1150% - 2300% over the coming years
Hello, OANDA:XAGUSD could face further downside, potentially dropping to around 28.68. If the price continues to reject the 1M pivot point, this decline seems inevitable. Let’s go! No Nonsense. Just Really Good Market Insights. Leave a Boost TradeWithTheTrend3344
Kirklands $NASDAQ:KIRK. A strong move may be brewing... The historical simple moving average (SMA) is flirting with the price and has yet to break the barrier - which often results in a sharp price increase. The downward trend is finally starting to reverse based on this measure, too. While it may not soar to crazy highs like in 2021, the chart setup is exactly what I like to see for an anticipated move up as it consolidates. A 12M float and 7% short interest could get the ball rolling if/when the price breaks into the historical SMA. Fundamentally, NASDAQ:KIRK is a small-cap with $114 million in sales. It recently partnered with NYSE:BYON as an exclusive licensee of Bed Bath & Beyond neighborhood stores, positioning the company as a multi-brand retailer. The first Bed Bath & Beyond neighborhood store is planned for a 2025 opening. Could this be the force for a future price move? Time will tell. At $1.99, NASDAQ:KIRK is in a personal buy zone. Target #1 = $2.50 Target #2 = $2.75 Target #3 = $3.00 Target #4 = $4.00
Looks like volatility is slowing down might see a small move to the upside.
daily, Trendline break + re-test Long 1.08 Stop 0.55 Target 2.9 Risk management is much more important than a good entry point. I am not a PRO trader. In my trading plan, the Max Risk of each short term trade should be less than 1% of an account.
COTI perfectly tested fib 0.5 lvl major resistance Moved back in uptrend channel and aiming for 0.25-0.26 targets and more COTI is an enterprise-grade fintech platform that Enables Cross-Chain Interoperations between other Blockchains like Ethereum, EOS, and others. Ethereum's run towards 5k - 7k will bring some other assets with it such as LDO, ETHFI and maybe COTI
NASDAQ:BITF This stock have been relatively unimpressive since its big rally in March 2024. Bitfarms Ltd. NASDAQ:BITF presents a compelling bullish opportunity for investors as the company positions itself for significant growth. Despite underwhelming performance since its March 2024 rally, recent developments suggest potential for higher prices in the months ahead. With Bitcoin crossing the $100,000 mark, Bitfarms is well-positioned to capitalize on increased cryptocurrency adoption. Its synthetic HODL strategy, which saw a 286% rise in long-dated Bitcoin call options, reflects confidence in higher Bitcoin prices, further supporting its bullish outlook In conclusion, Bitfarms’ strategic upgrades, market positioning, and Bitcoin’s bullish environment support a favorable outlook. Investors seeking exposure to the cryptocurrency mining sector may find NASDAQ:BITF an attractive candidate for medium- to long-term growth. I will post further Exit/ TP objective as we see NASDAQ:BITF move out of its current consolidation.
Long on turbo golden cross 50/200 EMA 100X, 0.69 cent i am targetting this bull rununtill jan 10 recenrtly listed on coin base, AI meme coin -with fund 69 doller created most memable meme coin in the history strong holding whale TA- showing HH and HL , retested multiple time recommended X to 10X if you are experience trader other wise buy on spot , DYOR dont be FOMO wait for daily LOW or LOWER LOW for good entry
Overall momentum is bearish, it has make a bearish flag. if Red line is break it will continue to bearish momentum